+

WO1990006115A3 - Preparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux - Google Patents

Preparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux Download PDF

Info

Publication number
WO1990006115A3
WO1990006115A3 PCT/EP1989/001425 EP8901425W WO9006115A3 WO 1990006115 A3 WO1990006115 A3 WO 1990006115A3 EP 8901425 W EP8901425 W EP 8901425W WO 9006115 A3 WO9006115 A3 WO 9006115A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxypurinol
alkali
alkaline earth
earth salts
preparations
Prior art date
Application number
PCT/EP1989/001425
Other languages
German (de)
English (en)
Other versions
WO1990006115A2 (fr
Inventor
Wolfgang Lahr
Guido Weickgenannt
Original Assignee
Henning Berlin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henning Berlin Gmbh filed Critical Henning Berlin Gmbh
Priority to DE8989912952T priority Critical patent/DE58905187D1/de
Priority to AT89912952T priority patent/ATE92321T1/de
Publication of WO1990006115A2 publication Critical patent/WO1990006115A2/fr
Publication of WO1990006115A3 publication Critical patent/WO1990006115A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des préparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux non cristallins contiennent la substance active sous forme d'une dispersion solide dans des additifs pharmacologiquement acceptables. Ces préparations sont plus rapidement et mieux solubles que l'oxypurinol et/ou que ses sels alcalins ou alcalino-terreux. On peut les utiliser pour fabriquer des médicaments contenant l'oxypurinol comme substance active sous une forme facilement assimilable par l'organisme.
PCT/EP1989/001425 1988-11-25 1989-11-24 Preparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux WO1990006115A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE8989912952T DE58905187D1 (de) 1988-11-25 1989-11-24 Zubereitungen des oxipurinols und/oder seiner alkali- oder erdalkalisalze.
AT89912952T ATE92321T1 (de) 1988-11-25 1989-11-24 Zubereitungen des oxipurinols und/oder seiner alkali- oder erdalkalisalze.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3839825.7 1988-11-25
DE3839825A DE3839825A1 (de) 1988-11-25 1988-11-25 Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze

Publications (2)

Publication Number Publication Date
WO1990006115A2 WO1990006115A2 (fr) 1990-06-14
WO1990006115A3 true WO1990006115A3 (fr) 1990-08-23

Family

ID=6367881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1989/001425 WO1990006115A2 (fr) 1988-11-25 1989-11-24 Preparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux

Country Status (5)

Country Link
EP (1) EP0445158B1 (fr)
JP (1) JP2965689B2 (fr)
DE (2) DE3839825A1 (fr)
ES (1) ES2058602T3 (fr)
WO (1) WO1990006115A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
DE4406462C2 (de) * 1994-02-24 1997-05-28 Jenapharm Gmbh Verfahren und Vorrichtung zur Herstellung fester Dispersionen
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2170289B1 (fr) * 2008-03-25 2012-02-15 Formac Pharmaceuticals N.v. Procédé de préparation de dispersions solides
WO2016010093A1 (fr) * 2014-07-16 2016-01-21 株式会社セラバリューズ Procédé de production de composite contenant de la curcumine amorphe et/ou un analogue de celle-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
DE2546371A1 (de) * 1975-10-16 1977-04-21 Sandoz Ag Neue galenische formen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1460302A (en) * 1973-05-23 1977-01-06 Wellcome Found Tablet formulation
GB2187954B (en) * 1986-03-13 1990-05-02 Wellcome Found Oxypurinol for use in cell protection.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
DE2546371A1 (de) * 1975-10-16 1977-04-21 Sandoz Ag Neue galenische formen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Band 83, Nr. 2, 14. Juli 1975, (Columbus, Ohio, US), J.H. COLLETT et al.: "Effects of Polyvinylpyrrolidone on the Solubility and Dissolution Rate of Allopurinol", siehe seite 340 *Zusammenfassung 15544t, & J. Pharm. Pharmacol. 1974, 26, Suppl., 84P-85P* *
Journal of Pharmaceutical Sciences, Band 60, Nr. 9, September 1971, WIN LOUNG CHIOU et al.: "Pharmaceutical Applications of Solid Dispersion Systems", pages 1281-1302 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion

Also Published As

Publication number Publication date
ES2058602T3 (es) 1994-11-01
JPH04502004A (ja) 1992-04-09
DE3839825C2 (fr) 1992-04-16
DE3839825A1 (de) 1990-06-13
WO1990006115A2 (fr) 1990-06-14
EP0445158A1 (fr) 1991-09-11
DE58905187D1 (de) 1993-09-09
JP2965689B2 (ja) 1999-10-18
EP0445158B1 (fr) 1993-08-04

Similar Documents

Publication Publication Date Title
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
CA2117351A1 (fr) Methode de fabrication permettant d'accroitre la durete des comprimes
IE871584L (en) Sustained release capsule.
IE871981L (en) Programmed release formulation.
EP0348808A3 (fr) Formulations pharmaceutiques et procédé pour leur préparation
AU576563B2 (en) Pyridazine derivatives
AU692430B2 (en) Aqueous pharmaceutical preparations of G-CSF with a long shelf life
CA2102630A1 (fr) Compositions pharmaceutiques de medicaments compactes
MY101177A (en) Improvements in pharmaceutically acceptable salts
CA2343376A1 (fr) Formulations de ranolazine a liberation lente
CA2232450A1 (fr) Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee
GB2264640B (en) Microcrystalline cellulose spheroids comprising hydromorphone and a sugar
CA2152795A1 (fr) Excipient de glucomannane de konjac a liberation-retard et rapidement utilisable
EP0995434A3 (fr) Formulations d'aérosols à usage médical
HUT50794A (en) Herbicides comprising substituted benztriazole derivatives as active ingredient and process for producing the active ingredients
AU3856193A (en) Sustained release preparations
CA2376226A1 (fr) Nouvelle formulation
WO1990006115A3 (fr) Preparations d'oxypurinol et/ou de ses sels alcalins ou alcalino-terreux
CA2093666A1 (fr) Preparation pharmaceutique sans solvant pour administration par voie orale permettant une liberation prolongee de l'ingredient actif et methode de fabrication de ladite preparation
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
AU3992589A (en) Annelated tetrahydropyridine acetic acid derivatives, the preparation and use thereof
ES483894A1 (es) Un procedimiento para la preparacion de una sal de adicion -de acido de un derivado de androstano.
IE781032L (en) Pharmaceutical compositions
AU7095687A (en) Pellet-containing pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989912952

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989912952

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989912952

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载